ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis. BahnRS, BurchHB, CooperDS, GarberJR, GreenleeMC, KleinI, LaurbergP, McDougallIR, MontoriVM, RivkeesSA, RossDS, SosaJA, StanMN. 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 21:593–646.
2.
WartofskyL, GlinoerD, SolomonB, NagatakiS, LagasseR, NagayamaY, IzumeM. 1991. Differences and similarities on the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid, 1:129–135.
RomãoR, RubioIGS, TomimoriEK, CamargoRYA, Medeiros-NetoG. 2009. High prevalence of side effects after recombinant human thyrotropin stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid, 19:945–951.
5.
BogazziF, VittiP. 2008. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease?Nat Clin Pract Endocrinol Metab, 4:70–71.
6.
LaurbergP, WallinG, TallstedtL, Abraham-NordlingM, LundellG, TorringO. 2008. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol, 158:69–75.
7.
LeiteAC, PedroABP, RomaldiniJH. 2011. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCLA10 in hyperthyroid patients with Graves' disease. Horm Metab Res, 43:194–199.
8.
ElbersL, MouritsM, WiersingaW. 2011. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid, 21:279–283.
9.
MazzaE, CarliniM, FlecchiaD, BlattoA, ZuccariniO, GambaS, BeninatiS, MessinaM. 2008. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest, 31:866–872.
10.
AziziF, AtaleL, HedayatiM, MehrabiY, ShiekholeslamiF. 2005. Effect of long-term continuous methimazole treatment of thyrotoxicosis comparison with radioiodine. Eur J Endocrinol, 152:695–701.
11.
MagnerJ. 2008. Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med, 359:1738–1739.
12.
FastS, NielsenVE, BonnemaSJ, HegedusL. 2009. Time to reconsider nonsurgical therapy of benign non-toxic muldinodular goiter: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol, 160:517–528.
13.
SosaJA, BowmanHM, TielschJM, PoweNR, GordonTA, UdelsmanR. 1998. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg, 228:320–330.
14.
BlissR, PatelN, GuineaA, ReeveTS, DelbridgeL. 1999. Age is no contraindication to thyroid surgery. Age Ageing, 28:363–366.
15.
SosaJA, MehtaPJ, WangTS, YeoHL, RomanSA. 2007. Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg, 246:1083–1091.
16.
RivkeesSA, DinauerC. 2007. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab, 92:797–800.
BiondiB, CooperDS. 2008. The clinical significance of subclinical thyroid dysfunction. Endocr Rev, 29:76–131.
19.
AbalovichM, AminoN, BarbourLA, CobinRH, De GrootLJ, MandelSJ, Stagnaro-GreenA. 2007. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 92:S1–47.
RivkeesSA, SzarfmanA. 2010. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab, 95:3260–3267.
22.
BarberoP, ValdezR, RodríguezH, TiscorniaC, MansillaE, AllonsA, CollS, LiascovichR. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case–control study. Am J Med Genet Part A, 146A:2390–2395.
23.
MomotaniN, NohJY, IshikawaN, ItoK. 1997. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab, 82:3633–3636.
24.
BartalenaL. 2011. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab, 96:592–599.
25.
LyttonSD, PontoKA, KanitzM, MatheisN, KohnLD, KahalyGJ. 2010. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab, 95:2123–2131.
26.
BrombergN, RomaldiniJH, WernerRS, SgarbiJA, WernerMC. 1992. The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triidothyronine. J Endocrinol Invest, 15:191–195.
